MX2020002015A - Sales de un compuesto y sus formas cristalinas. - Google Patents

Sales de un compuesto y sus formas cristalinas.

Info

Publication number
MX2020002015A
MX2020002015A MX2020002015A MX2020002015A MX2020002015A MX 2020002015 A MX2020002015 A MX 2020002015A MX 2020002015 A MX2020002015 A MX 2020002015A MX 2020002015 A MX2020002015 A MX 2020002015A MX 2020002015 A MX2020002015 A MX 2020002015A
Authority
MX
Mexico
Prior art keywords
crystalline forms
compound
salt
pyrido
morpholin
Prior art date
Application number
MX2020002015A
Other languages
English (en)
Inventor
Wenji Li
Zhenping Wu
Ling Feng
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of MX2020002015A publication Critical patent/MX2020002015A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención pertenece al campo farmacéutico y proporciona las sales farmacéuticamente aceptables del compuesto (S)-7-(4-(1-(metil sulfonil)piperidin-4-il)fenil)-N-(morfolin-2-il metil)pirido[3,4-b]pirazin-5-amina y las formas cristalinas de los mismos, los solvatos y las formas cristalinas de los mismos, las composiciones farmacéuticas que comprenden los mismos, así como los métodos de preparación de los mismos y el uso de los mismos.
MX2020002015A 2017-08-22 2018-08-22 Sales de un compuesto y sus formas cristalinas. MX2020002015A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710723169.3A CN109422741A (zh) 2017-08-22 2017-08-22 化合物的盐及其晶型
PCT/CN2018/101699 WO2019037737A1 (en) 2017-08-22 2018-08-22 CRYSTALLINE SALTS AND FORMS OF A COMPOUND

Publications (1)

Publication Number Publication Date
MX2020002015A true MX2020002015A (es) 2020-07-20

Family

ID=65439343

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002015A MX2020002015A (es) 2017-08-22 2018-08-22 Sales de un compuesto y sus formas cristalinas.

Country Status (20)

Country Link
US (3) US11396507B2 (es)
EP (1) EP3672972A4 (es)
JP (1) JP7162964B2 (es)
KR (1) KR102650181B1 (es)
CN (4) CN109422741A (es)
AU (1) AU2018320010B2 (es)
CA (1) CA3072525A1 (es)
CL (1) CL2020000439A1 (es)
EA (1) EA202090532A1 (es)
IL (1) IL272835B1 (es)
MX (1) MX2020002015A (es)
MY (1) MY200551A (es)
NZ (1) NZ761801A (es)
PE (1) PE20200887A1 (es)
PH (1) PH12020500366A1 (es)
SG (1) SG11202001301RA (es)
TW (1) TWI816690B (es)
UA (1) UA125942C2 (es)
WO (1) WO2019037737A1 (es)
ZA (1) ZA202001029B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114835682B (zh) * 2022-06-17 2024-04-26 华东理工常熟研究院有限公司 一种吡虫啉的盐及其制备方法与用途
TW202541805A (zh) * 2023-12-28 2025-11-01 大陸商和記黃埔醫藥（上海）有限公司 一種醫藥組成物及其應用
WO2025208443A1 (en) * 2024-04-02 2025-10-09 Hutchmed Limited Methods of treatment warm autoimmune hemolytic anemia using sovleplenib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012167423A1 (en) * 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
CN105732596B (zh) * 2012-11-19 2019-05-28 齐鲁制药有限公司 N-[3-氯-4-(3-氟苄氧基)苯基]-6-[5-[[2-(甲亚磺酰基)乙基]氨基]甲基]-2-呋喃基]-4-喹唑啉胺多晶型物及其制备方法

Also Published As

Publication number Publication date
TWI816690B (zh) 2023-10-01
EA202090532A1 (ru) 2021-02-11
NZ761801A (en) 2026-03-27
CN114044776A (zh) 2022-02-15
JP7162964B2 (ja) 2022-10-31
WO2019037737A1 (en) 2019-02-28
CN109422741A (zh) 2019-03-05
US11396507B2 (en) 2022-07-26
UA125942C2 (uk) 2022-07-13
KR102650181B1 (ko) 2024-03-21
MY200551A (en) 2024-01-03
CL2020000439A1 (es) 2020-08-07
AU2018320010A1 (en) 2020-02-27
PE20200887A1 (es) 2020-09-03
EP3672972A4 (en) 2021-03-24
US20240391918A1 (en) 2024-11-28
PH12020500366A1 (en) 2021-01-11
US20210047318A1 (en) 2021-02-18
US12084441B2 (en) 2024-09-10
CN111094284A (zh) 2020-05-01
TW201912642A (zh) 2019-04-01
BR112020003617A2 (pt) 2020-09-01
CN114369093A (zh) 2022-04-19
SG11202001301RA (en) 2020-03-30
IL272835A (en) 2020-04-30
AU2018320010B2 (en) 2022-09-15
CN114044776B (zh) 2024-12-17
EP3672972A1 (en) 2020-07-01
JP2020532510A (ja) 2020-11-12
CN114369093B (zh) 2024-12-17
ZA202001029B (en) 2022-07-27
CA3072525A1 (en) 2019-02-28
IL272835B1 (en) 2026-03-01
KR20200044020A (ko) 2020-04-28
US20220389012A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
MX2023001876A (es) Derivados de rapamicina.
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
PY1923494A (es) Derivados de n-(3-(7h-pirrolo[2,3-d]pirimidin-4-il)fenil)benzamida
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
UY33501A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
CO7131357A2 (es) Compuestos de n-ariltriazol como antagonistas de lpar
ECSP14013215A (es) Compuestos novedosos
UY36265A (es) “derivados de pirrolo[2,3-d]pirimidina”.
CO7131358A2 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
DOP2017000209A (es) Derivados de heteroarilo bicíclico fusionados con actividad como inhibidores de phd
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
ECSP16074478A (es) Compuestos novedosos
UY37160A (es) COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6
CO2020004977A2 (es) Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa
UY35535A (es) ?Derivados de fenil sulfonamidas?.
BR112017020081A2 (pt) análogos deuterados de etifoxina, seus derivados e usos dos mesmos
MX2018002738A (es) Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4.
MX2017002913A (es) Formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)oxi)-n,2-dim etilbenzofuran-3-carboxamida.
CL2020000439A1 (es) Sales de un compuesto y sus formas cristalinas.
AR099766A1 (es) Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos
MX2020003832A (es) Compuestos heteroarilos como moduladores alostericos positivos del receptor muscarinico m1.
CL2020002703A1 (es) Formas cristalinas de un compuesto
ECSP18056196A (es) Derivados de indano